Retatrutide Research Update: Triple-Receptor Evidence in 2026

Retatrutide (LY3437943) is an investigational peptide designed to activate glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Peer-reviewed Phase 2 results and 2026 Phase 3 topline announcements make it one of the most closely watched compounds in metabolic research, but it remains unapproved by regulatory agencies.

At a glance

• Retatrutide activates GIP, GLP-1, and glucagon receptors.
• A peer-reviewed Phase 2 trial included 338 adults and reported dose-dependent weight reduction.
• TRIUMPH-1 is listed as a completed Phase 3 study; additional Phase 3 topline results were announced in 2026.
• Company topline results are informative but are not a substitute for complete peer-reviewed data.
• Retatrutide remains investigational and unapproved.

Why researchers call it a triple-receptor agonist

Retatrutide is engineered to engage three hormone-receptor systems in one molecule. GLP-1 receptor activity is associated with glucose-dependent insulin secretion, delayed gastric emptying, and appetite regulation. GIP receptor activity adds another incretin signal. Glucagon receptor activity is being studied for its effects on energy expenditure and liver metabolism.

That combination is scientifically distinct from single GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. It is also why shorthand such as "GLP-3" should be treated as a commercial or educational label rather than a formal pharmacological name.

What the peer-reviewed Phase 2 trial found

A 48-week, randomized, double-blind, placebo-controlled Phase 2 trial enrolled 338 adults with obesity or overweight plus a weight-related condition. The primary endpoint was percentage change in body weight at 24 weeks, with additional outcomes assessed at 48 weeks.

In the published trial, the 12 mg group had a mean body-weight change of -24.2% at 48 weeks. Gastrointestinal adverse events were the most frequently reported and were generally dose related. The authors also reported dose-dependent increases in heart rate that peaked at 24 weeks and then declined.

What changed in 2026

ClinicalTrials.gov lists TRIUMPH-1 as a completed Phase 3 study with 2,335 participants. In May and July 2026, Eli Lilly announced positive topline results from several Phase 3 TRIUMPH studies, including TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3.

Topline company announcements are not the same as complete peer-reviewed publications. They can update the development picture, but detailed methods, subgroup analyses, and complete adverse-event data still require conference presentation, regulatory review, and journal publication.

Evidence boundaries

Retatrutide remains investigational and unapproved. Results from controlled clinical trials cannot establish the identity, purity, sterility, or dose accuracy of products sold outside the sponsor's clinical-development program.

Health Canada specifically warns consumers about unauthorized injectable peptide products, including products marketed as retatrutide or labelled for research use only. That regulatory warning should be considered separately from the scientific value of studying the molecule.

Bottom line

Retatrutide has moved beyond early proof-of-concept research and now has a substantial clinical-development program. The strongest public evidence includes a peer-reviewed Phase 2 trial, completed Phase 3 studies, and 2026 topline results. The compound is still unapproved, and complete Phase 3 publications and regulatory review remain essential before clinical conclusions are finalized.

Editorial standard: Sources were checked against the linked publication, trial registry, regulator, or sponsor page. Regulatory status and ongoing-trial information can change; this page is dated so readers can judge its currency.